Sheema Hashem

Sheema Hashem

Auto-generated profile, based on publicly available information

Sheema Hashem

Sidra Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
SNSabah Nisar
Sabah Nisar
SHSheema Hashem
Sheema Hashem
MMMUZAFAR AHMAD MACHA
MUZAFAR AHMAD MACHA
SYSantosh K. Yadav
Santosh K. Yadav
SMSankavi Muralitharan
Sankavi Muralitharan
LALubna Azeez
Lubna Azeez
Cancer cell biology takes advantage of identifying diverse cellular signaling pathways that are disrupted in cancer. Signaling pathways are an important means of communication from the exterior of cell to intracellular mediators, as well as intracellular interactions that govern diverse cellular processes. Oncogenic mutations or abnormal expression of signaling components disrupt the regulatory networks that govern cell function, thus enabling tumor cells to undergo dysregulated mitogenesis, to resist apoptosis, and to promote invasion to neighboring tissues. Unraveling of dysregulated signaling pathways may advance the understanding of tumor pathophysiology and lead to the improvement of targeted tumor therapy. In this review article, different signaling pathways and how their dysregulation contributes to the development of tumors have been discussed.

2 August 2023
Verified
Book Chapter
Closed access
PDF file
IKInamu Rashid Khan
Inamu Rashid Khan
FAFaizyana Ali
Faizyana Ali
SHSheema Hashem
Sheema Hashem
AAAlanoud Abdulla
Alanoud Abdulla
SNSabah Nisar
Sabah Nisar
MMMUZAFAR AHMAD MACHA
MUZAFAR AHMAD MACHA

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
Ajaz Ahmad BhatAjaz Ahmad Bhat
Ajaz Ahmad Bhat
TMTariq Masoodi
Tariq Masoodi
DMDeepika Mishra
Deepika Mishra
MSMayank Singh
Mayank Singh
SNSabah Nisar
Sabah Nisar
MHMohammad Haris
Mohammad Haris
Introduction: Head and neck squamous cell carcinoma (HNSCC) is categorized into Human Papilloma Virus positive (HPV+ve) and negative (HPV-ve) tumors, with the latter being more aggressive and displaying poor overall survival (OS). There is a need to identify aggressive biomarkers for patient stratification and improved patient care. Materials and Methods: Using the multi-omics data, including somatic mutations, copy number alterations, RNA sequencing, miRNA sequencing, and methylation from 513 HNSCC patients, we performed an integrative clustering analysis to differentiate HPV+ve and HPV-ve tumors and identify novel prognostic biomarkers for survival and treatment response. Using artificial intelligence (AI) based machine learning approach by implementing scikit-learn, we developed a model to predict the patient's OS. Results: Our clustering analysis robustly segregated HNSCC patients into HPV+ve and HPV-ve tumors. Artificial intelligence-based machine learning model identified a 30 gene signature panel specific to HPV-ve tumors precisely predicting poor OS with an accuracy of 90.5±0.8% (95% CI) and AUC of 80.2%. Furthermore, the multivariate Cox regression survival model identified 12 genes as independent prognostic biomarkers in HPV-ve tumors, including overexpression of novel genes NT5E and TRIML2. Interestingly, higher expression of NT5E and TRIML2 due to promoter hypomethylation predicted therapy resistance in 62.8% and 65.1% of HNSCC patients, respectively. The prognostic signature panel of 30 genes was further validated using three additional expression data sets (n = 450) of HNSCC. Conclusion: Our multi-omics and AI analysis revealed a novel HPV-ve molecular cluster with implications for predicting disease aggressiveness, therapeutic response, and OS in HNSCC patients. Citation Format: Ajaz A. Bhat, Tariq Masoodi, Deepika Mishra, Mayank Singh, Sabah Nisar, Sheema Hashem, Sana K. Baba, Puneet Bagga, Ravinder Reddy, Davide Bedognetti, Shahab Uddin, Wael El-Rifai, Muzafar A. Macha, Mohammad Haris. Tandem use of multi-omics and artificial intelligence identified novel prognostic and therapeutic biomarkers for head and neck squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6221.